NCT05804227View on ClinicalTrials.gov

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 20, 2023

Primary Completion Date

September 22, 2025

Study Completion Date

September 22, 2027

Conditions
Gliomas
Interventions
DRUG

Ulixertinib

Participants will take ulixertinib by mouth 2 times every day until the night before your surgery.

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

BioMed Valley Discoveries, Inc

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05804227 - Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas | Biotech Hunter | Biotech Hunter